STOCK TITAN
  1. Home
  2. Sec-filings
  3. MESO
  4. [6-K] Mesoblast Limited American Current Report (Foreign Issuer)

[6-K] Mesoblast Limited American Current Report (Foreign Issuer)

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
6-K
Rhea-AI Filing Summary
Analyzing...
Positive
  • None.
Negative
  • None.

Filing content is currently unavailable.

Source: View Original Filing on SEC EDGAR

Stock MESO logo
Mesoblast

NASDAQ:MESO

MESO Rankings

#2940 Ranked by Market Cap
N/A Ranked by Dividends

MESO Latest News

Jul 17, 2025
Successful Commercial Launch of Ryoncil®
Jun 30, 2025
Mesoblast and FDA Align on Key Items for Revascor® Biologic License Application in Ischemic Heart Failure
Jun 11, 2025
Mesoblast Maintains Momentum With FDA on Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure and Label Extension for Ryoncil® in Adults With GvHD
May 14, 2025
FDA Provides Seven Years of Orphan-Drug Exclusive Approval for Ryoncil®
Apr 29, 2025
Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2025

MESO Latest SEC Filings

Jul 14, 2025
[6-K] Mesoblast Limited American Current Report (Foreign Issuer)
Jul 1, 2025
[6-K] Mesoblast Limited American Current Report (Foreign Issuer)

MESO Stock Data

1.41B
127.54M
0.07%
2.49%
1.95%
Biotechnology
Healthcare
Link
Australia
Melbourne